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Aluminium is a hot topic in the current debate. Exposure occurs due to environmental, dietary and intentional
exposure to aluminium, such as in vaccines where it was introduced in 1926. In spite of the fact that it is a typical
Th2 adjuvant, aluminium redirects the immune response in systemic allergen immunotherapy (SIT) upon prolonged
immunization. SIT in the US, and SLIT in general, are at present non-adjuvanted therapies, but in Europe aluminium
is used as adjuvant in most SIT preparations. It enhances the safety of SIT by local deposition of the allergen.
Undesired properties of aluminium adjuvants comprise acute and chronic inflammation at the injection site, its
Th2 immune stimulatory capacity, its accumulation besides biodistribution in the body. The adjuvant and safety
profile of aluminium adjuvants in allergy vaccines are discussed, as well as the need for putting modern delivery
systems and adjuvants on the fast track.
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When and why aluminium adjuvants were introduced
into medicine
Glenny et al. reported the first time that aluminium, in a
potassium salt form, could be of use in vaccine prepara-
tions in 1926, when it was induced to enhance the
immunogenicity of toxoid preparations [1]. Later, several
studies compared different aluminium compounds, espe-
cially focusing on aluminium hydroxide versus alumin-
ium phosphate as adjuvants (AlADJ). Since then the most
important vaccines were formulated and tested with
aluminium hydroxide, such as diphtheria toxin, [2], or
diphtheria with tetanus toxoid [3]. Today most important
vaccines approved by the US Food and Drug Adminis-
tration are formulated with aluminium hydroxide [4]
(Table 1), and at least for primary immunizations AlADJ
has a superior activity, although may be less important for
booster immunizations. Also in veterinary medicine
aluminium hydroxide is in broad use (rev. by [5] (Table 2).
Further, the depot effect of AlADJ was recognized, improved
by formulation with monostearate and exploited inCorrespondence: Erika.jensen-jarolim@meduniwien.ac.at
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unless otherwise stated.antibiotics applications against syphilis [6], gonorrhea [7]
or other infections [8]. Last not least, aluminium hydroxide
was introduced for the healing and prevention of gastric
ulcers [9,10], bowel fistulas [11], and its superior proton
buffer capacity as compared to other compounds was
recognized experimentally in a dog model [12].Review
Mechanism of aluminium adjuvants in systemic allergen
immunotherapy
Type I allergy is characterized by specific IgE, a typical
Th2 skewing associated with IL-4, IL-13 cytokines,
sometimes accompanied by eosinophilic inflammation. It
is understood today that systemic allergen immunotherapy
(SIT) leads to a counterbalance of Th2 type immunity
by enhancement of Th1 responses and/or induction of
immune tolerance by T- and B-regulatory cells, accom-
panied by IL-10, IFNγ and TGFβ production [13,14].
Systemic allergen immunotherapy (SIT) is the only
causative treatment available today. It is a long-term
treatment over years and tackles the problem via both,
the subcutaneous (SCIT) or sublingual (SLIT) routes
[15]. It is also known that often in the onset of SIT IgE
levels are even enhanced when AlADJ are used, whereas
prolonged immunization lead to “modified Th2 immunity”al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Vaccines licenced in the US containing aluminum
in adjuvants [4]
Vaccines with aluminium adjuvant Vaccines without
aluminium adjuvant
DTP (diphtheria-tetanus-pertussis vaccine) Inactivated Polio Virus
DTaP (diphtheria-tetanus-acellular pertussis vaccine) Measles vaccine
Hib (Haemophilus influenzae type b)
conjugate vaccines (not all)
Mumps vaccine
Pneumococcal conjugate vaccine Rubella vaccine (MMR),
Hepatitis B vaccines Varicella vaccine
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consensus about a downregulation of specific IgE, it is ac-
cepted since long that the induction of IgG, especially the
non-inflammatory IgG4, is a hallmark of allergen immuno-
therapy [16]. No convincing data are available today that
indicate that any of the changes in antibody subclass, of
the investigated cytokines or factors do correlate with the
clinical outcome and can be regarded as a biomarker.
In fact, when Noon and Freeman experimented in
1911 with the inoculation of allergen extracts as prophy-
lactic vaccines [17,18], they did not use aluminium com-
pounds. AlADJ was first introduced into allergy vaccines
in 1937 [19]. Since, several authors investigated different
aluminium forms, such as aluminium hydroxide (Al(OH)3),
aluminium phosphate (AlPO4), or aluminium monostearate
[20], with focus on precipitation capacity and depot effects
of the adjuvants [21]. Today, AlADJ are used as adjuvant in
European allergy vaccines, whereas in the US allergy
vaccines are adjuvant free and soluble [22].
The boost of allergy by immunizations with AlADJ was
well-known even since the time before the discovery of
the IgE immunoglobulin class, and was studied in animal
and human models [23-26]. It was also recognized thatTable 2 Vaccines licensed for the use in animals
containing aluminum (adapted from [5])
Viral vaccines Bacterial vaccines
Avian infectious bronchitis virus Bacteriodes nosodus
Canine hepatitis virus Bordetella bronchispetica
Foot-and-mouth Disease Clostridia (diverse)
Newcastle Disease Virus Leptospira interrogans
Pasteurella multocidavaccination with an independent antigen with aluminium
could pre-determine the type of immunity to a consecu-
tive antigen. For instance, rats that were immunized with
Pertussis toxin and Al(OH)3 showed an increased “re-
aginic response” (IgE) to the allergen ovalbumin [27]. This
“non-specific enhancement of allergy” by a vaccine was
later confirmed in rats but the authors showed that the
effect was independent on aluminium adjuvant [28].
When (still in 1972) young healthy men were experi-
mentally immunized with allergoids of rye grass pollen
group 1 allergens in combination with AlADJ, they devel-
oped type I skin hypersensitivity, specific histamine
releasability, and passively transferable IgE antibodies
[29]. The study subjects, however, did not develop clin-
ical symptoms, possibly due to the fact that also “agglu-
tinating antibodies” (IgG) were formed, which according
to todays’ point of view might act as blocking antibodies.
After this human model it was shown in a dog model,
that sensitization to 2,4-dinitrobenzene conjugated to
ovalbumin led to IgE formation, which was associated
with bronchial constriction upon allergen challenge
when the IgE levels were only high enough [30]. It was
reported in the same year, that the immune response in
other mammalians may differ: when cows were treated
by a vaccine to foot-and-mouth disease virus formulated
in Al(OH)3 they produced reaginic and hemagglutinating
antibodies, but there was no correlation of each param-
eter to the size of the intradermal test reaction [31].
Itaya and collegues confirmed in mice that aluminium
compounds were excellent adjuvants for IgE induction,
whereas other adjuvants including LPS were not. Inter-
estingly, when the adjuvants including AlADJ were given
before sensitization, they suppressed a consecutive aller-
gic response [32].
Further, it was reported that in rabbits i.m. injections
with both aluminium hydroxide and aluminium phos-
phate led to increased Al levels in the blood already after
1 hour, and that after 28 days 3x more of the Al(OH)3
remained absorbed in the body, in the following tissues:
kidney > spleen > liver > heart > lymph node > brain [33].
Today, most subcutaneous allergen immunotherapy is
performed with Al(OH)3 as adjuvant, less by calcium
phosphate, but none of the SLIT preparations contains
any adjuvants [22]. Other formulations, like probiotics,
mycobacteria (attenuated or ghosts), virosomes, TLR
ligands, cochleates, proticles, etc. are still in the experi-
mental stage [34,35].
Effects and side effects of aluminium in allergy vaccination
When using AlADJ for formulating allergens for SIT, pro-
longed immunization leads to the induction of allergen-
specific IgG which finally dominates the IgE response [36].
The need for prolonged immunizations in SIT may be due
to the difficulty to modify an already established Th2
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ity by prophylactic vaccine. The induced IgG dampen the
allergic response via inhibiting the IgE-allergen interaction
and associated facilitated allergen presentation [37], and
they compete with IgE by quantity rather than quality: the
affinity of IgG to important allergens like Bet v 1 and Phl
p 5, is significantly lower than that of IgE [38]. The follow-
ing major features are attributed to AlADJ: i) in vaccine
formulations at neutral pH aluminium compounds are
positively charged and absorb negatively charged proteins
by electrostatic mechanism of which the strength will
depend on the avidity of interaction [39]; ii) AlADJ via ad-
sorption and entrapment formulates the allergen also into
nano- or microparticles which are preferentially taken up
by phagocytes through innate mechanisms involving mast
cells and macrophages, and may involve the inflamma-
some [40-42]. This leads to an immediate release of
inflammatory Th1 and Th2 cytokines, with endogenous
IL-18 facilitating IL-4 production [43]. The immunomod-
ulatory properties that include the innate and adaptive
branch of the immune system are reviewed in great detail
in [44]; iii) AlADJ increase phagocytosis of the allergen by
DCs, which interestingly in the absence of DC activation
leads to antigen presentation after 6 h [45]; iv) AlADJ pre-
cipitate the allergen, forming a depot [1], from where the
allergen is released slowly [39]. The local deposition pre-
vents immediate release of allergens in the hypersensitive
patient and contributes to safety of AlADJ.
Surprisingly, recently Al(OH)3 in comparison to the
Th1 adjuvant Montanide induced almost the same
humoral immune response to Adeno-associated virus-
like particles, except that the formation of IgG2a and
IgG2b were more pronounced by Montanide [46]. In
earlier studies AlADJ was compared head-to-head to
other adjuvants and showed superior effects when used
in a ragweed pollen [47] or birch pollen vaccine [48].
Given the paradox fact that Th2-biasing AlADJ in SIT
are used to cure a Th2 type disease, from the immuno-
logical point of view it is astonishing that these adju-
vants can achieve the observed high efficacy [39]. Still,
the outcome of SIT could be improved by avoiding
boosting of IgE and by redirecting the immune system
more effectively, and possibly this altogether could
shorten its duration. It has therefore been suggested that
allergen immunotherapy could be improved by addition
of immunopotentiating substances redirecting the im-
mune reactivity to Th1, or being immunomodulatory by
their particulate nature [49], pronounced TLR binding
capacity [50], or through their muco-adhesive properties
[22]. Important to note that in preclinical studies most
often prophylactic models are used which do not resem-
ble the setting in an already sensitized patient with
flowering Th2 immune response. Therefore, for proof of
concept studies rather therapeutic models should befavored. In fact, in a therapeutic mouse model an oral
vaccine based on grass pollen allergens entrapped in
microparticles was able to modify an already established
allergic response when the vaccine was targeted to mu-
cosal M-cells. This approach was independent on usage
of AlADJ [51]. Alternative adjuvants may also be needed
when in addition to high antibody levels also induction of
cytotoxic T-cell responses and a higher degree of antigen
presentation are desired [52], such as in cancer vaccines.
Only minor side effects have been reported so far for
allergy vaccines [53] in context with AlADJ, such as local
pruritic nodules which may be acute and transient in
33-70% of injections [54], and which sometimes persist
as granules [55,56]. Generally it is believed that the local
inflammation due to a vaccine shot is important for in-
duction of an efficient immune response. More recently,
the induction of contact dermatitis to aluminium itself
upon vaccination could be proven by skin testing in
5/78 children and 3/127 adults [57].
Aluminium exposure, dosage and undesired effects
Aluminium is an abundant compound in our environ-
ment in the “aluminium age” [58]. Many novel materials
are imprinted with nanoparticulate aluminium to pro-
mote their comfort of use, such as textiles or toothpaste.
Still, the physical and chemical forms of aluminium deter-
mine its bioavailability and hence toxicity. In the insoluble
form aluminium compounds may form particles, which
lead to inflammation upon ingestion or respiration.
The intakes in drinking water vary largely [59] but
may in some areas exceed 15 times the World Health
Organization recommendations for tolerable weekly intake
(TWI). The solubility depends on the pH and may at acidic
pH even reach 90 mg/L. It may be airborne at levels
between 0.0005 μg/m3 (arctic levels) to 1 μg/m3 (industrial
area) [60]. Also food and feed-intake and -additives
contribute to aluminium consumption. Altogether, the
European Food Safety Agency determined the TWI to
1 mg/kg body weight from all sources of aluminium
[61]. Breast milk contains 0.04 mg/L aluminium. There-
fore, until the age of 6 months breast-fed infants have con-
sumed 7,2 mg aluminium totally, formula-fed 38 mg and
soy-fed up to 112 mg, because soy is a plant that accumu-
lates aluminium [62].
A hot topic in the current debate is that aluminium is
introduced into the body by vaccines. In the US 0.85,
and in cases of documented efficacy up to 1.25 mg per
single vaccine shot are recommended [63], in Europe up
to 1.25 mg [4]. For instance, vaccination patient infor-
mation platforms put this amount in relation to 4.4 mg
derived from vaccines during the same time slot in a
baby’s life [64]. In SCIT with up to 54 injections during
the whole course the accumulating dose may vary between
45 and 67,5 mg of aluminium [53].
Figure 1 Representative lumogallion staining of cryosectioned
(6 μm section) THP-1 cells co-cultured with 50 μg/mL AlO(OH)
Brenntag adjuvant for 24 h. Cell sections were incubated for 24 h
in 100 μM lumogallion, 50 mM PIPES, pH 7.4. Slides were mounted
with ProLong® Gold Antifade Reagent with DAPI. Lumogallion (orange)
and DAPI-staining (blue) is depicted. The insert shows a close-up of an
individual cell and white arrows highlight distinguishable adjuvant
particles. Magnification X 1000. Kindly provided by Dr. Matthew Mold
and Dr. Chris Exley, Birchall Centre, Keele, UK.
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minium, including ions, soluble aluminium, particulate
forms, alone or bound to antigen or tissue compounds
can be found [44]. The injected AlADJ releases the bio-
logically active form Al3+ and aluminate (Al(OH)4
−) ions,
which may react with water and finally lead to Al super-
oxide production [65]. However, most of the injected
aluminium will be phagocytized and thereby activate
cells that recruit even more inflammatory cells. Due to a
high binding affinity with iron, aluminium intracellularly
can deplete the mitochondria from Fe and lead to the
production of reactive oxygen species (ROS). Aluminium
can induce DNA damage through ROS and has an apop-
totic effect. This has been shown for peripheral lympho-
cytes, which are susceptible especially in the G0/G1
phase of the cell cycle [66]. However, the amount of sol-
uble Al locally after a vaccine injection may be insuffi-
cient to induce cell death [44]. It might be considered
that aluminium-containing vaccines expose children in
an age when both, immune function and brain develop-
ment are sensitive [67].
The bidirectional exchange of cytokines and factors
between brain and immune system has been recognized
[68], and also phagocytosis of aluminium particles and
trafficking of these cells from muscle into the brain has
been reported [69]. Hence it is not surprising that
aluminium intake has been discussed in context with
neurologic disorders since a long time, especially
Alzheimer. Ferritin represents a major storage of iron in
mammalians and it has been recognized recently that
aluminium may replace iron within this complex [70].
By mass spectrometry the authors found that the alu-
minium content in ferritin was higher in Alzheimer pa-
tients and depended on the disease stage. The enhanced
intake via drinking in some geographical areas has been
associated with the development of Alzheimer [59].
However, taken the available data together, the evidence
seems to this end not entirely convincing [65], which to
a part might be caused by methodological limitations. A
specific aluminium-staining methodology was lacking
so far and has only recently been developed using a
fluorescent molecular probe for aluminium, lumogallion
[71] (Figure 1).
One should remember that also orally taken antiacid
drugs or sucralfate contain significant amounts of alu-
minium compounds. We could show that oral intakes of
these aluminium compounds support Th2 sensitization
to food proteins in mouse models of food allergy [72,73].
More recently, the so-called macrophagic myofasciitis
has been attributed to the persistence of aluminium
salts at injections sites in muscle [53], also chronic
fatigue syndrome [74] and autoimmune diseases have
been associated with aluminium intake, being termed
ASIA – Autoimmune/inflammatory syndrome inducedby adjuvants [75]. The groups with elevated risk include,
besides patients with a previous history of autoimmunity,
patients with allergy according to a recent paper [76].
In a comprehensive review on the present topic it was
therefore suggested to refine the TWI aluminium dose,
to reduce aluminium in parenteral solutions for infants
(where it led to defects in bone mineralization), to
harmonize occupational doses and to reconsider its use
in vaccines [65].Conclusion
Aluminium has been used since 1926 in human and
veterinary medicine and since 1937 in allergy and can
generally be regarded as safe in terms of acute local or
systemic side effects. The reports on chronic toxicity of
aluminium, however, including ASIA are accumulating
and are discussed seriously by national authorities, for
instance as France [77], Austria [78], or the US [63].
Therefore, it is proposed here that novel and promising
immunomodulators and allergen delivery systems that
are in the pipeline should be put on the fast track.Competing interests
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